MGC026 is an investigational, clinical ADC incorporating a B7-H3-targeting antibody and a novel topoisomerase I inhibitor-based linker-payload, SYNtecan E™. This cleavable linker payload is based on exatecan, a clinically-validated and potent camptothecin that readily combines with Synaffix’s Hydr...
$康方生物(09926)$•MGC026是一种临床 B7-H3 靶向 ADC,与 exatecan 进行位点特异性偶联,exatecan 是一种由 Synaffix(龙沙公司旗下)开发的拓扑异构酶 I 抑制剂有效载荷。vobra duo 和 MGC026 具有不同的作用机制,可以解决不同的癌症、肿瘤阶段,或与替代药物联合使用,或可能相互结合使用,以提高其临床效用。MGC...